Interleukin-33 regulates intestinal inflammation by modulating macrophages in inflammatory bowel disease

Scientific Reports

Volumn 7, Issue 1, 2017, Pages

  Seo, Dong Hyuk ^a,b   Che, Xiumei ^a,b   Kwak, Min Seob ^b,c   Kim, Soochan ^a,b   Kim, Jae Hyeon ^a,b   Ma, Hyun Woo ^a,b   Kim, Da Hye ^a,b   Kim, Tae Il ^a   Kim, Won Ho ^a   Kim, Seung Won ^a,b   Cheon, Jae Hee ^a,b  

^a Yonsei University   (South Korea)

^b Yonsei University College of Medicine   (South Korea)

^c Kyung Hee University Hospital   (South Korea)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIINFLAMMATORY AGENT; INTERLEUKIN 1 RECEPTOR LIKE 1 PROTEIN; INTERLEUKIN 33;

ANIMAL; BLOOD; C57BL MOUSE; CELL CULTURE; DRUG EFFECT; GOBLET CELL; HT-29 CELL LINE; HUMAN; INFLAMMATORY BOWEL DISEASE; INTESTINE; MACROPHAGE; MALE; METABOLISM; MOUSE; PATHOLOGY;

ANIMALS; ANTI-INFLAMMATORY AGENTS; CELLS, CULTURED; GOBLET CELLS; HT29 CELLS; HUMANS; INFLAMMATORY BOWEL DISEASES; INTERLEUKIN-1 RECEPTOR-LIKE 1 PROTEIN; INTERLEUKIN-33; INTESTINES; MACROPHAGES; MALE; MICE; MICE, INBRED C57BL;

EID: 85018781441     PISSN: None     EISSN: 20452322     Source Type: Journal    
DOI: 10.1038/s41598-017-00840-2     Document Type: Article

References (59)

1. Palmer, G., Gabay, C. Interleukin-33 biology with potential insights into human diseases. Nat Rev Rheumatol 7, 321-329, doi:10.1038/nrrheum.2011.53 (2011).
2. Pastorelli, L., et al. Epithelial-derived IL-33 and its receptor ST2 are dysregulated in ulcerative colitis and in experimental Th1/Th2 driven enteritis. Proc Natl Acad Sci USA 107, 8017-8022, doi:10.1073/pnas.0912678107 (2010).
3. Ajdukovic, J., et al. Interleukins IL-33 and IL-17/IL-17A in patients with ulcerative colitis. Hepatogastroenterology 57, 1442-1444 (2010).
4. Beltran, C. J., et al. Characterization of the novel ST2/IL-33 system in patients with inflammatory bowel disease. Inflamm Bowel Dis 16, 1097-1107, doi:10.1002/ibd.21175 (2010).
5. Kobori, A., et al. Interleukin-33 expression is specifically enhanced in inflamed mucosa of ulcerative colitis. J Gastroenterol 45, 999-1007, doi:10.1007/s00535-010-0245-1 (2010).
6. Seidelin, J. B., et al. IL-33 is upregulated in colonocytes of ulcerative colitis. Immunol Lett 128, 80-85, doi:10.1016/j.imlet.2009.11.001 (2010).
7. Pushparaj, P. N., et al. Interleukin-33 exacerbates acute colitis via interleukin-4 in mice. Immunology 140, 70-77, doi:10.1111/imm.12111 (2013).
8. Liew, F. Y., Pitman, N. I., McInnes, I. B. Disease-associated functions of IL-33: The new kid in the IL-1 family. Nat Rev Immunol 10, 103-110, doi:10.1038/nri2692 (2010).
9. Sedhom, M. A., et al. Neutralisation of the interleukin-33/ST2 pathway ameliorates experimental colitis through enhancement of mucosal healing in mice. Gut 62, 1714-1723, doi:10.1136/gutjnl-2011-301785 (2013).
10. Waddell, A., et al. IL-33 Signaling Protects from Murine Oxazolone Colitis by Supporting Intestinal Epithelial Function. Inflamm Bowel Dis 21, 2737-46, doi:10.1097/MIB.0000000000000532 (2015).
11. Duan, L., et al. Interleukin-33 ameliorates experimental colitis through promoting Th2/Foxp3(+) regulatory T-cell responses in mice. Mol Med 18, 753-761, doi:10.2119/molmed.2011.00428 (2012).
12. Imaeda, H., et al. Interleukin-33 suppresses Notch ligand expression and prevents goblet cell depletion in dextran sulfate sodiuminduced colitis. Int J Mol Med 28, 573-578, doi:10.3892/ijmm.2011.718 (2011).
13. Grobeta, P., Doser, K., Falk, W., Obermeier, F., Hofmann, C. IL-33 attenuates development and perpetuation of chronic intestinal inflammation. Inflamm Bowel Dis 18, 1900-1909, doi:10.1002/ibd.22900 (2012).
14. Sattler, S., et al. IL-10-producing regulatory B cells induced by IL-33 (Breg(IL-33)) effectively attenuate mucosal inflammatory responses in the gut. J Autoimmun 50, 107-122, doi:10.1016/j.jaut.2014.01.032 (2014).
15. Oboki, K., et al. IL-33 is a crucial amplifier of innate rather than acquired immunity. Proc Natl Acad Sci USA 107, 18581-18586, doi:10.1073/pnas.1003059107 (2010).
16. Okamoto, R., Watanabe, M. Molecular and clinical basis for the regeneration of human gastrointestinal epithelia. J Gastroenterol 39, 1-6, doi:10.1007/s00535-003-1259-8 (2004).
17. Van der Sluis, M., et al. Muc2-deficient mice spontaneously develop colitis, indicating that MUC2 is critical for colonic protection. Gastroenterology 131, 117-129, doi:10.1053/j.gastro.2006.04.020 (2006).
18. Gordon, S. Alternative activation of macrophages. Nat Rev Immunol 3, 23-35, doi:10.1038/nri978 (2003).
19. Kinoshita, K., Taupin, D. R., Itoh, H., Podolsky, D. K. Distinct pathways of cell migration and antiapoptotic response to epithelial injury: Structure-function analysis of human intestinal trefoil factor. Mol Cell Biol 20, 4680-4690, doi:10.1128/MCB.20.13.4680-4690.2000 (2000).
20. Stein, M., Keshav, S., Harris, N., Gordon, S. Interleukin 4 potently enhances murine macrophage mannose receptor activity: A marker of alternative immunologic macrophage activation. J Exp Med 176, 287-292, doi:10.1084/jem.176.1.287 (1992).
21. Maizels, R. M., Pearce, E. J., Artis, D., Yazdanbakhsh, M., Wynn, T. A. Regulation of pathogenesis and immunity in helminth infections. J Exp Med 206, 2059-2066, doi:10.1084/jem.20091903 (2009).
22. Kurowska-Stolarska, M., et al. IL-33 amplifies the polarization of alternatively activated macrophages that contribute to airway inflammation. J Immunol 183, 6469-6477, doi:10.4049/jimmunol.0901575 (2009).
23. Carriere, V., et al. IL-33, the IL-1-like cytokine ligand for ST2 receptor, is a chromatin-associated nuclear factor in vivo. Proc Natl Acad Sci USA 104, 282-287, doi:10.1073/pnas.0606854104 (2007).
24. Best, W. R., Becktel, J. M., Singleton, J. W. Rederived values of the eight coefficients of the Crohn's Disease Activity Index (CDAI). Gastroenterology 77, 843-846 (1979).
25. Cheon, J. H., et al. Development, validation, responsiveness of a novel disease activity index for intestinal Behçet's disease. Inflammatory Bowel Diseases 17, 605-613, doi:10.1002/ibd.21313 (2011).
26. Dieleman, L. A., et al. Dextran sulfate sodium-induced colitis occurs in severe combined immunodeficient mice. Gastroenterology 107, 1643-1652, doi:10.1016/0016-5085(94)90803-6 (1994).
27. Zaiss, D. M., Gause, W. C., Osborne, L. C., Artis, D. Emerging functions of amphiregulin in orchestrating immunity, inflammation, tissue repair. Immunity 42, 216-226, doi:10.1016/j.immuni.2015.01.020 (2015).
28. Wohlfert, E. A., et al. GATA3 controls Foxp3(+) regulatory T cell fate during inflammation in mice. J Clin Invest 121, 4503-4515, doi:10.1172/JCI57456 (2011).
29. Schiering, C., et al. The alarmin IL-33 promotes regulatory T-cell function in the intestine. Nature 513, 564-568, doi:10.1038/nature13577 (2014).
30. Monticelli, L. A., et al. IL-33 promotes an innate immune pathway of intestinal tissue protection dependent on amphiregulin-EGFR interactions. Proc Natl Acad Sci USA 112, 10762-10767, doi:10.1073/pnas.1509070112 (2015).
31. Xavier, R. J., Podolsky, D. K. Unravelling the pathogenesis of inflammatory bowel disease. Nature 448, 427-434, doi:10.1038/nature06005 (2007).
32. Abraham, C., Cho, J. H. Inflammatory bowel disease. N Engl J Med 361, 2066-2078, doi:10.1056/NEJMra0804647 (2009).
33. Cario, E. Toll-like receptors in inflammatory bowel diseases: A decade later. Inflamm Bowel Dis 16, 1583-1597, doi:10.1002/ibd.21282 (2010).
34. Vandenbroucke, R. E., et al. Matrix metalloproteinase 13 modulates intestinal epithelial barrier integrity in inflammatory diseases by activating TNF. EMBO Mol Med 5, 932-948, doi:10.1002/emmm.201202100 (2013).
35. Katz, J. P., et al. The zinc-finger transcription factor Klf4 is required for terminal differentiation of goblet cells in the colon. Development 129, 2619-2628 (2002).
36. Schmitz, J., et al. IL-33, an interleukin-1-like cytokine that signals via the IL-1 receptor-related protein ST2 and induces T helper type 2-associated cytokines. Immunity 23, 479-490, doi:10.1016/j.immuni.2005.09.015 (2005).
37. Besnard, A. G., et al. IL-33-mediated protection against experimental cerebral malaria is linked to induction of type 2 innate lymphoid cells, M2 macrophages and regulatory T cells. PLoS Pathog 11, e1004607, doi:10.1371/journal.ppat.1004607 (2015).
38. Brint, E. K., et al. ST2 is an inhibitor of interleukin 1 receptor and Toll-like receptor 4 signaling and maintains endotoxin tolerance. Nat Immunol 5, 373-379, doi:10.1038/ni1050 (2004).
39. Ortiz-Masia, D., et al. iNOS-derived nitric oxide mediates the increase in TFF2 expression associated with gastric damage: Role of HIF-1. FASEB J 24, 136-145, doi:10.1096/fj.09-137489 (2010).
40. Cayrol, C., Girard, J. P. The IL-1-like cytokine IL-33 is inactivated after maturation by caspase-1. Proc Natl Acad Sci USA 106, 9021-9026, doi:10.1073/pnas.0812690106 (2009).
41. Riviere, E., et al. Pitfalls for detecting interleukin-33 by ELISA in the serum of patients with primary Sjogren syndrome: Comparison of different kits. Ann Rheum Dis 75, 633-635, doi:10.1136/annrheumdis-2015-208557 (2016).
42. Waddell, A., et al. IL-33 Signaling Protects from Murine Oxazolone Colitis by Supporting Intestinal Epithelial Function. Inflamm Bowel Dis 21, 2737-2746, doi:10.1097/MIB.0000000000000532 (2015).
43. Martin, N. T., Martin, M. U. Interleukin 33 is a guardian of barriers and a local alarmin. Nat Immunol 17, 122-131, doi:10.1038/ni.3370 (2016).
44. Latiano, A., et al. Associations between genetic polymorphisms in IL-33, IL1R1 and risk for inflammatory bowel disease. PLoS One 8, e62144, doi:10.1371/journal.pone.0062144 (2013).
45. Hayakawa, H., Hayakawa, M., Kume, A., Tominaga, S. Soluble ST2 blocks interleukin-33 signaling in allergic airway inflammation. J Biol Chem 282, 26369-26380, doi:10.1074/jbc.M704916200 (2007).
46. Ho, J. E., et al. Common genetic variation at the IL1RL1 locus regulates IL-33/ST2 signaling. J Clin Invest 123, 4208-4218, doi:10.1172/JCI67119 (2013).
47. Chackerian, A. A., et al. IL-1 receptor accessory protein and ST2 comprise the IL-33 receptor complex. J Immunol 179, 2551-2555, doi:10.4049/jimmunol.179.4.2551 (2007).
48. Saenz, S. A., Taylor, B. C., Artis, D. Welcome to the neighborhood: Epithelial cell-derived cytokines license innate and adaptive immune responses at mucosal sites. Immunol Rev 226, 172-190, doi:10.1111/j.1600-065X.2008.00713.x (2008).
49. Van Klinken, B. J., Van der Wal, J. W., Einerhand, A. W., Buller, H. A., Dekker, J. Sulphation and secretion of the predominant secretory human colonic mucin MUC2 in ulcerative colitis. Gut 44, 387-393, doi:10.1136/gut.44.3.387 (1999).
50. Ghaleb, A. M., Katz, J. P., Kaestner, K. H., Du, J. X., Yang, V. W. Kruppel-like factor 4 exhibits antiapoptotic activity following gamma-radiation-induced DNA damage. Oncogene 26, 2365-2373, doi:10.1038/sj.onc.1210022 (2007).
51. Ghaleb, A. M., Aggarwal, G., Bialkowska, A. B., Nandan, M. O., Yang, V. W. Notch inhibits expression of the Kruppel-like factor 4 tumor suppressor in the intestinal epithelium. Mol Cancer Res 6, 1920-1927, doi:10.1158/1541-7786.MCR-08-0224 (2008).
52. Li, D., et al. IL-33 promotes ST2-dependent lung fibrosis by the induction of alternatively activated macrophages and innate lymphoid cells in mice. J Allergy Clin Immunol 134, 1422-1432, e1411, doi:10.1016/j.jaci.2014.05.011 (2014).
53. Malik, A., et al. IL-33 regulates the IgA-microbiota axis to restrain IL-1alpha-dependent colitis and tumorigenesis. J Clin Invest 126, 4469-4481, doi:10.1172/JCI88625 (2016).
54. Kobayashi, K., et al. Development of consensus statements for the diagnosis and management of intestinal Behçet's disease using a modified Delphi approach. Journal of Gastroenterology 42, 737-745, doi:10.1007/s00535-007-2090-4 (2007).
55. Nikolaus, S., Schreiber, S. Diagnostics of inflammatory bowel disease. Gastroenterology 133, 1670-1689, doi:10.1053/j. gastro.2007.09.001 (2007).
56. Silverberg, M. S., et al. Toward an integrated clinical, molecular and serological classification of inflammatory bowel disease: Report of a Working Party of the 2005 Montreal World Congress of Gastroenterology. Canadian journal of gastroenterology=Journal canadien de gastroenterologie 19(Suppl A), 5a-36a, doi:10.1155/2005/269076 (2005).
57. Auwerx, J. The human leukemia cell line, THP-1: A multifacetted model for the study of monocyte-macrophage differentiation. Experientia 47, 22-31, doi:10.1007/BF02041244 (1991).
58. Kim, S. W., et al. Bifidobacterium lactis inhibits NF-kappaB in intestinal epithelial cells and prevents acute colitis and colitisassociated colon cancer in mice. Inflamm Bowel Dis 16, 1514-1525, doi:10.1002/ibd.21262 (2010).
59. Weigmann, B., et al. Isolation and subsequent analysis of murine lamina propria mononuclear cells from colonic tissue. Nat Protoc 2, 2307-2311, doi:10.1038/nprot.2007.315 (2007).